Literature DB >> 31974201

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.

Jan Philipp Bewersdorf1, Smith Giri2, Rong Wang3, Robert T Williams4, Martin S Tallman5, Amer M Zeidan1, Maximilian Stahl6.   

Abstract

Keywords:  Acute Myeloid Leukemia; Hypomethylating agents; Leukemic Stem Cell; Meta-analysis; Venetoclax

Year:  2020        PMID： 31974201      PMCID： PMC7604631          DOI： 10.3324/haematol.2019.242826

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.

Authors:  S H Downs; N Black
Journal:  J Epidemiol Community Health       Date:  1998-06       Impact factor: 3.710

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

3.  Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.

Authors:  Ron Ram; Odelia Amit; Tsila Zuckerman; Ronit Gurion; Pia Raanani; Yael Bar-On; Irit Avivi; Ofir Wolach
Journal:  Ann Hematol       Date:  2019-06-11       Impact factor: 3.673

4.  Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Authors:  Maximilian Stahl; Michelle DeVeaux; Pau Montesinos; Raphael Itzykson; Ellen K Ritchie; Mikkael A Sekeres; John D Barnard; Nikolai A Podoltsev; Andrew M Brunner; Rami S Komrokji; Vijaya R Bhatt; Aref Al-Kali; Thomas Cluzeau; Valeria Santini; Amir T Fathi; Gail J Roboz; Pierre Fenaux; Mark R Litzow; Sarah Perreault; Tae Kon Kim; Thomas Prebet; Norbert Vey; Vivek Verma; Ulrich Germing; Juan Miguel Bergua; Josefina Serrano; Steven D Gore; Amer M Zeidan
Journal:  Blood Adv       Date:  2018-04-24

5.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

6.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

7.  Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Authors:  Ibrahim Aldoss; Dongyun Yang; Raju Pillai; James F Sanchez; Matthew Mei; Ahmed Aribi; Haris Ali; Karamjeet Sandhu; Monzr M Al Malki; Amandeep Salhotra; Samer Khaled; Weili Sun; Margaret O'Donnell; David Snyder; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Am J Hematol       Date:  2019-07-10       Impact factor: 10.047

8.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Authors:  Andrew H Wei; Stephen A Strickland; Jing-Zhou Hou; Walter Fiedler; Tara L Lin; Roland B Walter; Anoop Enjeti; Ing Soo Tiong; Michael Savona; Sangmin Lee; Brenda Chyla; Relja Popovic; Ahmed Hamed Salem; Suresh Agarwal; Tu Xu; Kaffa M Fakouhi; Rod Humerickhouse; Wan-Jen Hong; John Hayslip; Gail J Roboz
Journal:  J Clin Oncol       Date:  2019-03-20       Impact factor: 44.544

9.  Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Authors:  Chezi Ganzel; Zhuoxin Sun; Larry D Cripe; Hugo F Fernandez; Dan Douer; Jacob M Rowe; Elisabeth M Paietta; Rhett Ketterling; Michael J O'Connell; Peter H Wiernik; John M Bennett; Mark R Litzow; Selina M Luger; Hillard M Lazarus; Martin S Tallman
Journal:  Am J Hematol       Date:  2018-08       Impact factor: 13.265

10.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.